MA54877A - Compositions et méthodes comprenant un agoniste de récepteur 5ht destinées au traitement de troubles psychologiques, cognitifs, comportementaux et/ou d'humeur - Google Patents

Compositions et méthodes comprenant un agoniste de récepteur 5ht destinées au traitement de troubles psychologiques, cognitifs, comportementaux et/ou d'humeur

Info

Publication number
MA54877A
MA54877A MA054877A MA54877A MA54877A MA 54877 A MA54877 A MA 54877A MA 054877 A MA054877 A MA 054877A MA 54877 A MA54877 A MA 54877A MA 54877 A MA54877 A MA 54877A
Authority
MA
Morocco
Prior art keywords
psychological
behavioral
cognitive
compositions
treatment
Prior art date
Application number
MA054877A
Other languages
English (en)
Inventor
Judith Blumstock
William J Tyler
Original Assignee
Diamond Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Diamond Therapeutics Inc filed Critical Diamond Therapeutics Inc
Publication of MA54877A publication Critical patent/MA54877A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/572—Five-membered rings
    • C07F9/5728—Five-membered rings condensed with carbocyclic rings or carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
    • A61K36/258—Panax (ginseng)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Psychiatry (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Inorganic Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Nanotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Emergency Medicine (AREA)
  • Botany (AREA)
  • Biophysics (AREA)
  • Addiction (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA054877A 2019-01-30 2020-01-29 Compositions et méthodes comprenant un agoniste de récepteur 5ht destinées au traitement de troubles psychologiques, cognitifs, comportementaux et/ou d'humeur MA54877A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962799010P 2019-01-30 2019-01-30
US201962798998P 2019-01-30 2019-01-30

Publications (1)

Publication Number Publication Date
MA54877A true MA54877A (fr) 2021-12-08

Family

ID=71841404

Family Applications (1)

Application Number Title Priority Date Filing Date
MA054877A MA54877A (fr) 2019-01-30 2020-01-29 Compositions et méthodes comprenant un agoniste de récepteur 5ht destinées au traitement de troubles psychologiques, cognitifs, comportementaux et/ou d'humeur

Country Status (12)

Country Link
US (4) US20220096504A1 (fr)
EP (1) EP3917537A4 (fr)
JP (2) JP2022523700A (fr)
KR (1) KR20210134313A (fr)
CN (1) CN114040767A (fr)
AU (2) AU2020215150B8 (fr)
BR (1) BR112021014750A2 (fr)
CA (1) CA3127854A1 (fr)
IL (1) IL285186A (fr)
MA (1) MA54877A (fr)
MX (2) MX2021009037A (fr)
WO (1) WO2020157569A1 (fr)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL304040B2 (en) 2016-07-07 2024-09-01 Hughes Howard Med Inst Modified ligand-gated ion channels and methods of use
US12459965B2 (en) 2017-10-09 2025-11-04 Compass Pathfinder Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
SG11202004246YA (en) 2017-11-10 2020-06-29 Hughes Howard Med Inst Modified ligand-gated ion channels and methods of use
CA3132731A1 (fr) * 2019-03-07 2020-09-10 University Of Padova Compositions et methodes d'utilisation comprenant des substances ayant des actions de plasticite neurale administrees a des doses et formulations non psychedeliques/psychotomimetiques
US12377112B2 (en) 2019-04-17 2025-08-05 Compass Pathfinder Limited Methods of treating neurocognitive disorders, chronic pain and reducing inflammation
EP4003395A4 (fr) * 2019-07-23 2023-07-19 Caamtech, Inc. Compositions contenant des composés à base de sécrétions de crapaud
CA3152752A1 (fr) 2019-10-01 2021-04-08 Thomas Henley Genie genetique de champignons pour moduler l'expression de tryptamine
AU2020358869A1 (en) 2019-10-03 2022-04-14 Pike Therapeutics Usa, Inc. Transdermal delivery of dronabinol
US12409131B2 (en) 2019-10-03 2025-09-09 Pike Therapeutics Usa, Inc. Transdermal delivery of dronabinol
EP4041209A4 (fr) 2019-10-11 2024-01-24 Pike Therapeutics, Inc. Compositions transdermiques comprenant du cannabidiol (cbd) destinées à être utilisées dans le traitement de troubles épileptiques
US12016829B2 (en) 2019-10-11 2024-06-25 Pike Therapeutics Inc. Pharmaceutical composition and method for treating seizure disorders
CA3155181A1 (fr) 2019-10-14 2021-04-22 Pike Therapeutics, Inc., 1219014 B.C. Ltd. Administration transdermique de cannabidiol
US12121617B2 (en) 2019-10-14 2024-10-22 Pike Therapeutics Inc. Transdermal delivery of cannabidiol
US12268699B2 (en) 2019-10-14 2025-04-08 Pike Therapeutics Inc. Transdermal delivery of tetrahydrocannabinol
WO2021072530A1 (fr) * 2019-10-15 2021-04-22 Tassili Life Sciences, Corp. Formulations à libération contrôlée d'agents dérivés de psilocybes et leur procédé d'utilisation, et procédés et compositions pour traiter une lésion cérébrale traumatique légère avec un syndrome de stress post-traumatique
CA3160793A1 (fr) * 2019-12-04 2021-06-10 Neonmind Biosciences Inc. Utilisation de psilocine, de psilocybine ou analogues associes pour la perte de poids, le traitement de l'obesite et de l'hyperphagie boulimique
US20210220336A1 (en) * 2020-01-22 2021-07-22 Clexio Biosciences Ltd. Topical detomidine formulations
KR20220137081A (ko) 2020-02-04 2022-10-11 마인드셋 파마 인크. Cns 장애의 치료를 위한 세로토닌성 사이키델릭 작용제로서의 실로신 유도체
BR112022015379A2 (pt) 2020-02-04 2022-09-27 Mindset Pharma Inc Derivados de 3-pirrolidino-indol como agentes psicodélicos serotonérgicos para o tratamento de distúrbios do snc
EP4135713A4 (fr) * 2020-04-17 2024-04-17 Revive Therapeutics Ltd. Utilisation de psilocybine dans le traitement d'une lésion cérébrale neurologique et de migraines
WO2021225796A1 (fr) 2020-05-05 2021-11-11 Universitätsspital Basel Traitement par mdma destiné à améliorer le profil des effets émotionnels aigus du lsd, de la psilocybine ou d'autres substances psychédéliques
WO2021226416A1 (fr) 2020-05-08 2021-11-11 Psilera Inc. Nouvelles compositions de matière et compositions pharmaceutiques
US12240813B2 (en) 2020-05-19 2025-03-04 Cybin Irl Limited Deuterated tryptamine derivatives and methods of use
WO2021243460A1 (fr) * 2020-06-03 2021-12-09 Neonmind Biosciences Inc. Méthode thérapeutique de perte de poids
WO2022023812A1 (fr) * 2020-07-29 2022-02-03 Diamond Therapeutics Inc. Agonistes de récepteur 5-ht à libération prolongée pour des affections neurologiques
US20220062310A1 (en) * 2020-09-03 2022-03-03 Yale University Psilocybin in patients with obsessive-compulsive disorder
WO2022072808A1 (fr) * 2020-10-01 2022-04-07 Mydecine Innovations Group Inc. Nouvelles compositions psychédéliques, systèmes d'administration et leurs utilisations thrapeutiques
CA3197488A1 (fr) * 2020-10-12 2022-04-21 Goodcap Pharmaceuticals Ltd. Compositions pour la reduction de l'inflammation dans le but d'ameliorer ou d'entretenir la sante mentale ou physique
US12029718B2 (en) 2021-11-09 2024-07-09 Cct Sciences, Llc Process for production of essentially pure delta-9-tetrahydrocannabinol
US20230398234A1 (en) * 2020-10-28 2023-12-14 Mydecine Innovations Group Inc. Novel fungal compoind formulations and their therapeutic methods of use
WO2022115798A2 (fr) * 2020-11-30 2022-06-02 Wesana Health Inc. Compositions et méthodes de traitement de la migraine
WO2022115796A1 (fr) * 2020-11-30 2022-06-02 Wesana Health Inc. Compositions et méthodes de traitement de pathologies neurologiques
KR20230109765A (ko) 2020-12-09 2023-07-20 캄테크, 인크. 다이알킬 트립타민 및 이의 치료적 용도
CA3113240C (fr) 2020-12-28 2023-09-05 Psilo Scientific Ltd. Composition d'alcaloide psychoactif transmucosal et preparation connexe
US12534441B2 (en) 2021-01-15 2026-01-27 Beckley Psytech Limited Tryptamine analogues
EP4155306A1 (fr) 2021-01-15 2023-03-29 Beckley Psytech Limited Analogue neuroactif d'ergoline
US20220265601A1 (en) * 2021-02-10 2022-08-25 David Alan Heldreth, JR. Methods of use and formulations of allosteric modulators of the serotonin, dopamine and other receptor systems for medical, recreational, religious, research and other uses.
US11312684B1 (en) 2021-02-10 2022-04-26 Eleusis Therapeutics Us, Inc. Pharmaceutically acceptable salts of psilocin and uses thereof
US20220273628A1 (en) * 2021-02-19 2022-09-01 Universitätsspital Basel Effects of lysergic acid diethylamide (lsd) and of lsd analogs to assist psychotherapy for generalized anxiety disorder or other anxiety not related to life-threatening illness
US20220370413A1 (en) * 2021-03-06 2022-11-24 Mind Medicine, Inc. Formulations of psilocin that have enhanced stability
EP4304603A4 (fr) * 2021-03-08 2025-01-22 Diamond Therapeutics Inc. Titrage d'agonistes du récepteur sérotoninergique
WO2022204323A1 (fr) * 2021-03-24 2022-09-29 The Trustees Of Columbia University In The City Of New York Analogues d'ariadne non hallucinogènes pour le traitement de troubles neurologiques et psychiatriques
TW202304466A (zh) * 2021-03-30 2023-02-01 英商康派斯開拓者公司 賽洛西賓（ｐｓｉｌｏｃｙｂｉｎ）組成物，其製備方法及使用方法
CA3215871A1 (fr) * 2021-03-31 2022-10-06 Lyfe Chng, Llc Systeme transdermique, formulation et methode d'administration therapeutique d'un agent psychedelique
US20220331292A1 (en) * 2021-04-16 2022-10-20 Callitas Health Inc. Compositions and methods for delivery of psilocin and prodrugs thereof
WO2022221942A1 (fr) * 2021-04-19 2022-10-27 Betterlife Pharma Inc. Prévention du détournement de médicaments
EP4329759A4 (fr) 2021-04-30 2025-07-16 Mind Medicine Inc Formes cristallines de sels de lsd
JP2024517194A (ja) * 2021-05-03 2024-04-19 マインド メディシン， インコーポレイテッド サイケデリック薬の用量を漸増する方法
WO2022235514A1 (fr) * 2021-05-04 2022-11-10 Mind Medicine, Inc. Administration de psychotropes par liposome
WO2022261058A1 (fr) * 2021-06-07 2022-12-15 University Of Mississippi Procédés de distribution pulsée d'agents bioactifs
US11801256B2 (en) 2021-06-08 2023-10-31 Universitätsspital Basel Antidepressant-psilocybin co-treatment to assist psychotherapy
GB202109023D0 (en) * 2021-06-23 2021-08-04 Ldn Pharma Ltd Compositions comprising an agonist of 5-hydroxytryptamine (5-ht) receptor subtype 3
WO2022272176A1 (fr) * 2021-06-25 2022-12-29 Synaptive Therapeutics, Llc Analogues de psilocybine pour le traitement de troubles psychologiques
JP7846211B2 (ja) 2021-08-19 2026-04-14 デフィニウム セラピューティクス ユーエス， インコーポレイテッド 治療適用のためのｄ－リゼルグ酸ジエチルアミドの即時放出製剤
US12492178B2 (en) 2021-09-01 2025-12-09 Empathbio, Inc. Stable polymorph of R-MDMA HCl
EP4396162A4 (fr) * 2021-09-03 2025-11-12 Alexander Shulgin Res Institute Inc Allyl tryptamines asymétriques
US20230099972A1 (en) * 2021-09-30 2023-03-30 ATAI Life Sciences AG Compositions and methods for treating headaches
WO2023086962A1 (fr) * 2021-11-12 2023-05-19 Terran Biosciences Inc. Psilocybine et o-acétylpsilocine, leurs sels et formes à l'état solide
US20250011351A1 (en) 2021-11-12 2025-01-09 Terran Biosciences Inc. Psilocybin and o-acetylpsilocin, salts and solid state forms thereof
US11912680B2 (en) 2021-12-28 2024-02-27 Empathbio, Inc. Nitric oxide releasing prodrugs of MDA and MDMA
WO2023129956A2 (fr) 2021-12-30 2023-07-06 ATAI Life Sciences AG Analogues de diméthyltryptamine utilisés en tant que médicaments d'administration d'oxyde nitrique
CN118984868A (zh) 2021-12-31 2024-11-19 恩派瑞安神经科学公司 用于产生精神药物生物碱的遗传修饰的生物体
EP4463153A4 (fr) * 2022-01-12 2026-03-04 Eleusis Therapeutics Us Inc Formulation de benzoate de psilocine pour perfusion intraveineuse
WO2023168023A1 (fr) 2022-03-04 2023-09-07 Reset Pharmaceuticals, Inc. Co-cristaux ou sels comprenant de la psilocine
WO2023183618A1 (fr) * 2022-03-25 2023-09-28 Ojai Energetics Pbc Compositions psychédéliques et leurs procédés de formation
EP4514831A1 (fr) * 2022-04-27 2025-03-05 Howard Hughes Medical Institute Récepteurs chimiogénétiques et leurs procédés de fabrication et d'utilisation
US20250114383A1 (en) * 2022-05-13 2025-04-10 Reset Pharmaceuticals, Inc. Administration of a psychedelic compound by intravenous infusion
IL315086A (en) 2022-06-09 2024-10-01 Diamond Therapeutics Inc Amorphous (A-polymorphic) psilocybin
WO2023248222A1 (fr) * 2022-06-21 2023-12-28 Technion Research & Development Foundation Limited Agents modulateurs du récepteur 5-ht2c pour le traitement de troubles neurodégénératifs, mentaux, cognitifs et auto-immuns
US20240000795A1 (en) * 2022-06-30 2024-01-04 Terran Biosciences Inc. Methods and compositions relating to controlling psychedelic effects with serotonin receptor modulators
WO2024015447A1 (fr) * 2022-07-12 2024-01-18 Lobe Sciences Ltd. Préparation de sels, d'esters et de conjugués de psilocine stables et leurs utilisations
US12344583B2 (en) 2022-07-12 2025-07-01 Lobe Sciences Ltd. Solid psilocin salts
WO2024019908A1 (fr) * 2022-07-19 2024-01-25 Lobe Sciences Ltd. Agent psychédélique sérotoninergique pour le traitement du mutisme sélectif
US12264131B2 (en) 2022-08-19 2025-04-01 Beckley Psytech Limited Pharmaceutically acceptable salts and compositions thereof
WO2024079648A1 (fr) * 2022-10-11 2024-04-18 Sintalica S.R.L. Système d'administration pour la libération contrôlée d'un composé psychédélique, composition pharmaceutique et utilisations associées
WO2024151625A1 (fr) * 2023-01-10 2024-07-18 Georgetown University Compositions de plga non toxiques et leurs procédés de fabrication et d'utilisation
CN121358470A (zh) * 2023-02-23 2026-01-16 布莱特西德公司 用于调节g蛋白偶联受体的组合物和方法
US12246005B2 (en) 2023-06-13 2025-03-11 Beckley Psytech Limited 5-methoxy-n,n-dimethyltryptamine (5-MeO-DMT) formulations
WO2025010308A2 (fr) * 2023-07-03 2025-01-09 Empathbio, Inc. Compositions d'énantiomère de mdma et méthodes de modulation de réponse aux agressions
WO2025024400A2 (fr) * 2023-07-21 2025-01-30 2A Biosciences, Inc. Tryptamines substituées et leurs utilisations
WO2025040932A1 (fr) * 2023-08-21 2025-02-27 Nechama Golan Guérison complète de toutes les maladies mentales à l'aide d'amide d'acide d-lysergique à différentes doses et durées de traitement
WO2026068690A1 (fr) * 2024-09-27 2026-04-02 Medichem, S.A. Injection à action prolongée de quétiapine

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4641942B2 (ja) * 2003-10-03 2011-03-02 フェーイレン・ナムローゼ・フェンノートシャップ ヒトおよび動物におけるｉｇｆ−１血清レベルの低下と関連した種々の疾患状態の治療用の治療用組成物の製造のための血清中ｉｇｆ−１レベルを増加できる化合物の使用
US20180021326A1 (en) * 2016-07-23 2018-01-25 Paul Edward Stamets Compositions and methods for enhancing neuroregeneration and cognition by combining mushroom extracts containing active ingredients psilocin or psilocybin with erinacines or hericenones enhanced with niacin
CN108619214A (zh) * 2017-03-15 2018-10-09 王慎君 一种治疗肿瘤的药物
GB2571696B (en) * 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
CA3132731A1 (fr) * 2019-03-07 2020-09-10 University Of Padova Compositions et methodes d'utilisation comprenant des substances ayant des actions de plasticite neurale administrees a des doses et formulations non psychedeliques/psychotomimetiques

Also Published As

Publication number Publication date
IL285186A (en) 2021-09-30
US20260053831A1 (en) 2026-02-26
KR20210134313A (ko) 2021-11-09
US20260053829A1 (en) 2026-02-26
BR112021014750A2 (pt) 2021-09-28
AU2025203049A1 (en) 2025-05-22
MX2025007468A (es) 2025-07-01
CA3127854A1 (fr) 2020-08-06
JP2025186241A (ja) 2025-12-23
WO2020157569A1 (fr) 2020-08-06
EP3917537A1 (fr) 2021-12-08
AU2020215150A1 (en) 2021-09-09
EP3917537A4 (fr) 2022-09-07
CN114040767A (zh) 2022-02-11
US20220096504A1 (en) 2022-03-31
MX2021009037A (es) 2021-10-13
AU2020215150A8 (en) 2025-07-03
JP2022523700A (ja) 2022-04-26
AU2020215150B2 (en) 2025-02-06
AU2020215150B8 (en) 2025-07-03
US20230113351A1 (en) 2023-04-13

Similar Documents

Publication Publication Date Title
MA54877A (fr) Compositions et méthodes comprenant un agoniste de récepteur 5ht destinées au traitement de troubles psychologiques, cognitifs, comportementaux et/ou d'humeur
EP3837359A4 (fr) Méthodes et compositions pour le traitement d'une maladie mitochondriale ou de troubles mitochondriaux et hétéroplasmie
MA28660B1 (fr) Composes et compositions en tant que modulateurs de ppar
EP3448389A4 (fr) Composés de quinazoline et d'indole destinés au traitement de troubles médicaux
MA56387A (fr) Dérivés de quinazoline-4-one utiles pour le traitement de maladies et de troubles associés à braf
MA54229A (fr) Composés et compositions destinés au traitement d'états pathologiques associés à une activité de nlrp
MA30339B1 (fr) Azolopyrimidines inhibitrices de l'activite du recepteur cannabinoïde 1
MA33604B1 (fr) Composés et compositions en tant qu'inhibiteurs de protéine kinase
EP3810135A4 (fr) Amélioration de l'administration d'agents actifs lipophiles à travers la barrière hémato-encéphalique et méthodes de traitement de troubles du système nerveux central
EP3876712A4 (fr) Modèles d'animaux, procédés de criblage, et procédés de traitement pour maladies ou troubles intraoculaires
EP3405215A4 (fr) Méthodes destinées au traitement de la maladie de danon et d'autres troubles liés à l'autophagie
EP3704108A4 (fr) Composés et compositions pour le traitement de troubles hématologiques
MA33593B1 (fr) Composés hétérocycliques et leurs utilisations
EP3749322A4 (fr) Composés et méthodes de traitement d'une dépendance et de troubles associés
EP3528852A4 (fr) Méthodes et compositions pour le traitement de la maladie de fabry
EP3906043A4 (fr) Procédés et compositions pour le traitement de la maladie de fabry
EP3700525A4 (fr) Administration améliorée d'antioxydants pour le traitement de troubles du système nerveux central impliquant un stress oxydatif
EP3692171A4 (fr) Utilisation d'anticorps dirigés contre une famille à similarité de séquence 19, élément a5, pour le traitement et le diagnostic des troubles de l'humeur
EP3927706A4 (fr) Composés d'imidazopyridinyle et leur utilisation pour le traitement de troubles prolifératifs
MX2020001855A (es) Composiciones farmacéuticas que contienen anticuerpos anti-beta-amiloides.
EP3934646A4 (fr) Compositions pharmaceutiques pour le traitement de maladies ou de troubles oculaires
EP3973586A4 (fr) Nouvelles compositions pharmaceutiques et méthodes de traitement de troubles mentaux, comportementaux et cognitifs
EP3672587A4 (fr) Compositions pharmaceutiques destinées au traitement d'affections ophtalmiques
EP1784191A4 (fr) Traitement de troubles psychologiques ou cognitifs employant un hypocholestérolémiant associé à un antidépresseur
EP3943107A4 (fr) Composition pour prévenir ou traiter une maladie du cerveau et du système nerveux